NCT03012165

A Study of ADX-102 in Subjects With Allergic Conjunctivitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 154 (actual)
• Sponsor: Aldeyra Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Phase 2b Evaluation of the Onset and Duration of ADX-102 Ophthalmic Drops (0.5% and 0.1%) Compared to Vehicle of ADX-102 Ophthalmic Drops in the Conjunctival Allergen Challenge (Ora-CAC®) Model of Acute Allergic Conjunctivitis.

Conditions

• Conjunctivitis, Allergic

Interventions

Type	Name	Description
DRUG	ADX-102 Ophthalmic Drops (0.5%)	ADX-102 Ophthalmic Drops (0.5%) administered twice in two weeks.
DRUG	ADX-102 Ophthalmic Drops (0.1%)	ADX-102 Ophthalmic Drops (0.1%) administered twice in two weeks.
DRUG	Vehicle of ADX-102 Ophthalmic Drops	Vehicle of ADX-102 Ophthalmic Drops administered twice in two weeks.

Timeline

• Start date: 2016-12-01
• Primary completion: 2017-05-01
• Completion: 2017-05-01
• First posted: 2017-01-06
• Last updated: 2023-01-09
• Results posted: 2023-01-09

Locations

5 sites across 1 country: United States